Relationship between Efficacy of Cetuximab and Skin Rashes: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

 ZHANGXiu-bao ¹ , XIANGRong-wu ¹ , ZHAOQing-chun ² , ZHANGJing-hai ¹ , HANJia-rong ¹ , YANGJing-yu ¹ , XIEMin-xiang ¹ ,  ZHAOMing-yi ¹

1. School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China;
2. Department of Pharmacy, General Hospital of Shenyang Military Region, Shenyang 110840, China;

Corresponding?author：

ZHAOMing-yi, Email: zmy_dl@126.com

Keywords：

Cetuximab; Skin rash; Efficacy; Systematic review; Meta-analysis

DOI：

10.7507/1672-2531.20150032

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the relationship between skin rashes and efficacy of cetuximab. Methods Such databases as PubMed, EMbase, The Cochrane Library (Issue 1, 2013), CBM, CNKI and VIP were systemically searched to collect literature on relationship between the severity of skin rashes and efficacy of cetuximab published up to Aug. 2013. According to the inclusion and exclusion criteria, two reviewers independently screened literature, extracted data, and evaluated methodological quality of included studies. Then meta-analysis was performed using RevMan 5.2 software. Results A total of 32 studies involving 1 543 patients were included. The results of metaanalysis showed that:the efficacy of cetuximab in patients with skin rashes was significantly superior to patients without skin rashes (RR=1.53, 95%CI 1.23 to 1.91, P=0.000 2); in addition, the efficacy of cetuximab in patients with severe skin rashes was significantly superior to patients with mild skin rashes (RR=2.42, 95%CI 1.89 to 3.11, P<0.000 01). Conclusion Skin rashes are significantly associated with better efficacy of cetuximab.

Citation： ZHANGXiu-bao, XIANGRong-wu, ZHAOQing-chun, ZHANGJing-hai, HANJia-rong, YANGJing-yu, XIEMin-xiang, ZHAOMing-yi. Relationship between Efficacy of Cetuximab and Skin Rashes: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2015, 15(2): 181-187. doi: 10.7507/1672-2531.20150032 Copy

1.	繆建華, 鐘皎, 過雪丹, 等. 西妥昔單抗聯合GP方案治療晚期非小細胞肺癌臨床觀察. 實用臨床醫藥雜志, 2012, 16(3):90-92.
2.	虞永峰, 陸舜. 表皮生長因子受體和血管內皮細胞生長因子受體之外肺癌靶向治療新進展, 腫瘤, 2010, 30(8):706-710.
3.	Tandon R, Kapoor S, Vali S, et al. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor:a novel approach for overcoming resistance in anticancer treatment. Eur J Pharmacol, 2011, 667(1-3):56-65.
4.	Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Enl J Med, 2004, 351(4), 337-345.
5.	Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors:a literature-based metaanalysis of 24 trials. Lung Cancer, 2012, 78(1):8-15.
6.	van Cutsem E, Lang ID, Haens G. et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer(mCRC)treated with FOLFIR1 with or without cetuximab:The CRYSTAL experience. J Clin Oneol, 2008, 26(20 Supp1):a2.
7.	陳耀龍, 蔡羽嘉, 王夢書. 循證醫學術語介紹Ⅱ. 中國循證醫學雜志, 2009, 9(2):143-146.
8.	張天嵩, 鐘文昭. 實用循證醫學方法學. 中南大學出版社, 2012, 7.
9.	艾昌林, 段玉蓉, Phil Wiffen, 等. 系統評價員選擇中文生物醫學期刊數據庫的策略研究. 中國循證醫學雜志, 2010, 10(6):749-753.
10.	Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. Available at:http://www.cochrane-handbook.org.
11.	Newcastle-Ottawa量表. 張天嵩, 鐘文昭, 主編. 實用循證醫學方法學. 第1版. 長沙:中南大學出版社, 2012:63-64.
12.	文進, 李幼平. Meta分析中效應尺度指標的選擇. 中國循證醫學雜志, 2007, 7(8):606-613.
13.	Boccia S, De Feo E, Galli P, et al. A systematic review evaluating the methodological aspects of meta-analyses of genetic association studies in cancer research. Eur J Epidemiol, 2010, 25(11):765-775.
14.	王丹, 翟俊霞, 牟振云, 等. Meta分析中的異質性及其處理方法. 中國循證醫學雜志, 2009, 9(10):1115-1118.
15.	Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med, 1997, 127(9):820-826.
16.	Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 1959, 22(4):719-748.
17.	魏麗娟, 董惠娟. Meta分析中異質性的識別與處理. 第二軍醫大學學報, 2006, 27(4):449-450.
18.	Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100:a phase Ⅲ trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol, 2009, 27(30):4966-4972.
19.	DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials, 1986, 7(3):177-188.
20.	Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994, 50(4):1088-1101.
21.	Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol, 2004, 5(11):647-647.
22.	Koo DH, Lee JL, Kim TW, et al. A Phase Ⅱ Study of Cetuximab (Erbitux^?) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer. J Korean Med Sci, 2007, 22(Suppl):S98-S103.
23.	Pinto C, di Fabio F, Siena S, et al. Phase Ⅱ study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol, 2007, 18(3):510-517.
24.	葉煌陽, 張映紅, 陳建清. 西妥昔單抗聯合化療在晚期結直腸癌一線治療中的療效觀察. 中國癌癥雜志, 2008, l8(9):704-706.
25.	應杰兒, 劉碧霞, 鐘海均. 轉移性結直腸癌西妥昔單抗治療的療效及安全性. 腫瘤學雜志, 2012, 18(5):345-348.
26.	Lu Z, Zhang X, Shen L, et al. Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer. The Chinese-German Journal of Clinical Oncology, 2008, 7(7):400-403.
27.	Racca P, Fanchini L, Caliendo V, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer:outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Canc, 2008, 7(1), 48-54.
28.	Secord AA, Blessing JA, Armstrong DK, et al. Phase Ⅱ trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression:a Gynecologic Oncology Group study. Gynecol Oncol, 2008, 108(3):493-499.
29.	張小田, 沈琳, 張曉東. 西妥昔單抗聯合化療在消化系統腫瘤中的臨床應用. 中華腫瘤雜志, 2008, 30(5):385-389.
30.	金璿, 白羽, 于晶琳. 西妥昔單抗聯合化療治療轉移性結直腸癌的臨床觀察. 腫瘤基礎與臨床, 2008, 21(4):286-290.
31.	張偉鋒, 劉連科, 劉怡茜. 西妥昔單抗聯合化療治療消化系統腫瘤的臨床研究. 中國現代藥物應用, 2008, 2(24):18-22.
32.	王琳, 秦叔逵, 錢軍. 西妥昔單抗聯合化療治療晚期結直腸癌的臨床觀察. 臨床腫瘤學雜志, 2009, 14(7):628-632.
33.	Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus:a randomized phase Ⅱ study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 2009, 20(10):1667-1673.
34.	Klinghammer K, Kn?dler M, Schmittel A, et al. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res, 2010, 16(1):304-310.
35.	Kullmann F, Hollerbach S, Dollinger MM. et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer:a multicentre phase Ⅱ study. Br J Cancer, 100(7):1032-1036.
36.	林榕波, 郭增清, 陳奕貴. 西妥昔單抗聯合伊立替康治療化療耐藥晚期結直腸癌. 中國癌癥雜志, 2008, 18(1):79-80.
37.	趙波濤. 西妥昔單抗聯合FOLFIRI方案治療化療耐藥晚期結直腸癌臨床療效觀察. 江西醫藥, 2010, 45(4):337-339.
38.	白利平, 劉忠臣, 齊忠權. 西妥昔單抗聯合化療初始治療22例轉移性結直腸癌的近期療效觀察. 中國腫瘤臨床, 2010, 34(4):220-224.
39.	王風云, 張艷橋, 張純惠. 西妥昔單抗聯合化療在治療大腸癌肝轉移中的療效觀察. 哈爾濱醫科大學學報, 2010, 44(1):77-81.
40.	李敏, 方明治, 錢垠. 西妥昔單抗聯合伊立替康為主方案治療轉移性結直腸癌. 腫瘤防治研究, 2010, 37(8):938-941.
41.	丘惠娟, 夏良平, 徐瑞華. 含Cetuximab方案治療10例胃癌或食管癌的近期療效分析. 腫瘤學雜志, 2010, 16(4):294-297.
42.	Dahan L, Norguet E, Etienne-Grimaldi MC, et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC cancer, 2011, 11(1):496-507.
43.	李建璜, 劉巍, 鐘美佐. 西妥昔單抗聯合化療治療晚期結直腸癌的近期療效觀察. 現代腫瘤醫學, 2011, 19(2):328-331.
44.	周琴, 宋潔, 吳克雄. 西妥昔單抗聯合化療治療轉移性結直腸癌的觀察. 中國醫藥, 2011, 6(12):1540-1543.
45.	王方, 王山川. 西妥昔單抗聯合FOLFOX4方案治療轉移性結直腸癌的臨床觀察. 中國藥物與臨床, 2011, 11(6):716-718.
46.	陸超敬. 西妥昔單抗聯合化療治療EGFR陽性表達中晚期食管癌患者的療效分析. 中國醫藥指南, 2011, 9(29):113-115.
47.	劉皈陽, 張鑫宇, 王偉蘭. 西妥昔單抗治療中晚期惡性腫瘤的療效和安全性評價. 中國醫院藥學雜志, 2011, 31(2):127-129.
48.	Dahan L, Norguet E, Etienne-Grimaldi MC, et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC cancer, 2011, 11(1):496.
49.	Hitt R, Irigoyen A, Cortes-Funes H, et al. Phase Ⅱ study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Annals of Oncology, 2013, 23(4):1016-1022.
50.	孫杰, 姜麗娜, 潘賽英. 西妥昔單抗聯合卡培他濱與奧沙利鉑治療晚期結直腸癌20例. 醫藥導報, 2012, 31(1):17-21.
51.	Jiménez B, Trigo JM, Pajares BI, et al. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral oncology, 2013, 49(2):182-185.
52.	O'byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC):data from the FLEX study. J Clin Oncol, 2009, 27(15S):8007.
53.	王萍, 謝蟪旭, 張綺, 等. 如何在Cochrane系統評價中設計資料提取表. 中國循證醫學雜志, 2011, 11(3):341-345.
54.	Blick SK, Scott LJ. Cetuximab:a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs, 2007, 67(17):2585-2607.
55.	Liu MJ, Zhou CX, Wang Z, et al. Analysis of adverse effect induced by cetuximab combined with radio-chemotherapy in 83 cancer patients. Chin J Mod Appl Pharm, 2011, 28(5):485-487.
56.	Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26(10):1626-1634.
57.	Moosmann N, von Weikersthal LF, Vehling-Kaiser U, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer:AIO KRK-0104-a randomized trial of the German AIO CRC Study Group. J Clin Oncol, 2011, 29:1050-1058.
58.	龍庭鳳, 何黎, 李云霞, 等. EGFRI抗腫瘤靶向藥物皮膚不良反應的表現和防治. 皮膚病與性病, 2012, 34(5):271-288.

1. 繆建華, 鐘皎, 過雪丹, 等. 西妥昔單抗聯合GP方案治療晚期非小細胞肺癌臨床觀察. 實用臨床醫藥雜志, 2012, 16(3):90-92.
2. 虞永峰, 陸舜. 表皮生長因子受體和血管內皮細胞生長因子受體之外肺癌靶向治療新進展, 腫瘤, 2010, 30(8):706-710.
3. Tandon R, Kapoor S, Vali S, et al. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor:a novel approach for overcoming resistance in anticancer treatment. Eur J Pharmacol, 2011, 667(1-3):56-65.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Enl J Med, 2004, 351(4), 337-345.
5. Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors:a literature-based metaanalysis of 24 trials. Lung Cancer, 2012, 78(1):8-15.
6. van Cutsem E, Lang ID, Haens G. et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer(mCRC)treated with FOLFIR1 with or without cetuximab:The CRYSTAL experience. J Clin Oneol, 2008, 26(20 Supp1):a2.
7. 陳耀龍, 蔡羽嘉, 王夢書. 循證醫學術語介紹Ⅱ. 中國循證醫學雜志, 2009, 9(2):143-146.
8. 張天嵩, 鐘文昭. 實用循證醫學方法學. 中南大學出版社, 2012, 7.
9. 艾昌林, 段玉蓉, Phil Wiffen, 等. 系統評價員選擇中文生物醫學期刊數據庫的策略研究. 中國循證醫學雜志, 2010, 10(6):749-753.
10. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. Available at:http://www.cochrane-handbook.org.
11. Newcastle-Ottawa量表. 張天嵩, 鐘文昭, 主編. 實用循證醫學方法學. 第1版. 長沙:中南大學出版社, 2012:63-64.
12. 文進, 李幼平. Meta分析中效應尺度指標的選擇. 中國循證醫學雜志, 2007, 7(8):606-613.
13. Boccia S, De Feo E, Galli P, et al. A systematic review evaluating the methodological aspects of meta-analyses of genetic association studies in cancer research. Eur J Epidemiol, 2010, 25(11):765-775.
14. 王丹, 翟俊霞, 牟振云, 等. Meta分析中的異質性及其處理方法. 中國循證醫學雜志, 2009, 9(10):1115-1118.
15. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med, 1997, 127(9):820-826.
16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 1959, 22(4):719-748.
17. 魏麗娟, 董惠娟. Meta分析中異質性的識別與處理. 第二軍醫大學學報, 2006, 27(4):449-450.
18. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100:a phase Ⅲ trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol, 2009, 27(30):4966-4972.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials, 1986, 7(3):177-188.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994, 50(4):1088-1101.
21. Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol, 2004, 5(11):647-647.
22. Koo DH, Lee JL, Kim TW, et al. A Phase Ⅱ Study of Cetuximab (Erbitux^?) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer. J Korean Med Sci, 2007, 22(Suppl):S98-S103.
23. Pinto C, di Fabio F, Siena S, et al. Phase Ⅱ study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol, 2007, 18(3):510-517.
24. 葉煌陽, 張映紅, 陳建清. 西妥昔單抗聯合化療在晚期結直腸癌一線治療中的療效觀察. 中國癌癥雜志, 2008, l8(9):704-706.
25. 應杰兒, 劉碧霞, 鐘海均. 轉移性結直腸癌西妥昔單抗治療的療效及安全性. 腫瘤學雜志, 2012, 18(5):345-348.
26. Lu Z, Zhang X, Shen L, et al. Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer. The Chinese-German Journal of Clinical Oncology, 2008, 7(7):400-403.
27. Racca P, Fanchini L, Caliendo V, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer:outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Canc, 2008, 7(1), 48-54.
28. Secord AA, Blessing JA, Armstrong DK, et al. Phase Ⅱ trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression:a Gynecologic Oncology Group study. Gynecol Oncol, 2008, 108(3):493-499.
29. 張小田, 沈琳, 張曉東. 西妥昔單抗聯合化療在消化系統腫瘤中的臨床應用. 中華腫瘤雜志, 2008, 30(5):385-389.
30. 金璿, 白羽, 于晶琳. 西妥昔單抗聯合化療治療轉移性結直腸癌的臨床觀察. 腫瘤基礎與臨床, 2008, 21(4):286-290.
31. 張偉鋒, 劉連科, 劉怡茜. 西妥昔單抗聯合化療治療消化系統腫瘤的臨床研究. 中國現代藥物應用, 2008, 2(24):18-22.
32. 王琳, 秦叔逵, 錢軍. 西妥昔單抗聯合化療治療晚期結直腸癌的臨床觀察. 臨床腫瘤學雜志, 2009, 14(7):628-632.
33. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus:a randomized phase Ⅱ study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 2009, 20(10):1667-1673.
34. Klinghammer K, Kn?dler M, Schmittel A, et al. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res, 2010, 16(1):304-310.
35. Kullmann F, Hollerbach S, Dollinger MM. et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer:a multicentre phase Ⅱ study. Br J Cancer, 100(7):1032-1036.
36. 林榕波, 郭增清, 陳奕貴. 西妥昔單抗聯合伊立替康治療化療耐藥晚期結直腸癌. 中國癌癥雜志, 2008, 18(1):79-80.
37. 趙波濤. 西妥昔單抗聯合FOLFIRI方案治療化療耐藥晚期結直腸癌臨床療效觀察. 江西醫藥, 2010, 45(4):337-339.
38. 白利平, 劉忠臣, 齊忠權. 西妥昔單抗聯合化療初始治療22例轉移性結直腸癌的近期療效觀察. 中國腫瘤臨床, 2010, 34(4):220-224.
39. 王風云, 張艷橋, 張純惠. 西妥昔單抗聯合化療在治療大腸癌肝轉移中的療效觀察. 哈爾濱醫科大學學報, 2010, 44(1):77-81.
40. 李敏, 方明治, 錢垠. 西妥昔單抗聯合伊立替康為主方案治療轉移性結直腸癌. 腫瘤防治研究, 2010, 37(8):938-941.
41. 丘惠娟, 夏良平, 徐瑞華. 含Cetuximab方案治療10例胃癌或食管癌的近期療效分析. 腫瘤學雜志, 2010, 16(4):294-297.
42. Dahan L, Norguet E, Etienne-Grimaldi MC, et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC cancer, 2011, 11(1):496-507.
43. 李建璜, 劉巍, 鐘美佐. 西妥昔單抗聯合化療治療晚期結直腸癌的近期療效觀察. 現代腫瘤醫學, 2011, 19(2):328-331.
44. 周琴, 宋潔, 吳克雄. 西妥昔單抗聯合化療治療轉移性結直腸癌的觀察. 中國醫藥, 2011, 6(12):1540-1543.
45. 王方, 王山川. 西妥昔單抗聯合FOLFOX4方案治療轉移性結直腸癌的臨床觀察. 中國藥物與臨床, 2011, 11(6):716-718.
46. 陸超敬. 西妥昔單抗聯合化療治療EGFR陽性表達中晚期食管癌患者的療效分析. 中國醫藥指南, 2011, 9(29):113-115.
47. 劉皈陽, 張鑫宇, 王偉蘭. 西妥昔單抗治療中晚期惡性腫瘤的療效和安全性評價. 中國醫院藥學雜志, 2011, 31(2):127-129.
48. Dahan L, Norguet E, Etienne-Grimaldi MC, et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC cancer, 2011, 11(1):496.
49. Hitt R, Irigoyen A, Cortes-Funes H, et al. Phase Ⅱ study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Annals of Oncology, 2013, 23(4):1016-1022.
50. 孫杰, 姜麗娜, 潘賽英. 西妥昔單抗聯合卡培他濱與奧沙利鉑治療晚期結直腸癌20例. 醫藥導報, 2012, 31(1):17-21.
51. Jiménez B, Trigo JM, Pajares BI, et al. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral oncology, 2013, 49(2):182-185.
52. O'byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC):data from the FLEX study. J Clin Oncol, 2009, 27(15S):8007.
53. 王萍, 謝蟪旭, 張綺, 等. 如何在Cochrane系統評價中設計資料提取表. 中國循證醫學雜志, 2011, 11(3):341-345.
54. Blick SK, Scott LJ. Cetuximab:a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs, 2007, 67(17):2585-2607.
55. Liu MJ, Zhou CX, Wang Z, et al. Analysis of adverse effect induced by cetuximab combined with radio-chemotherapy in 83 cancer patients. Chin J Mod Appl Pharm, 2011, 28(5):485-487.
56. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26(10):1626-1634.
57. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer:AIO KRK-0104-a randomized trial of the German AIO CRC Study Group. J Clin Oncol, 2011, 29:1050-1058.
58. 龍庭鳳, 何黎, 李云霞, 等. EGFRI抗腫瘤靶向藥物皮膚不良反應的表現和防治. 皮膚病與性病, 2012, 34(5):271-288.

Chinese Journal of Evidence-Based Medicine

Relationship between Efficacy of Cetuximab and Skin Rashes: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content